Capricor Therapeutics(US:CAPR) Prnewswireยท2025-07-23 15:26Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Capricor Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its lead drug candidate, deramiocel, and its FDA approval process [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Capricor between October 9, 2024, and July 10, 2025, to discuss their legal rights [1][2]. - A federal securities class action has been filed against Capricor, with a deadline of September 15, 2025, for investors to seek the role of lead plaintiff [2][7]. Group 2: Allegations Against Capricor - The complaint alleges that Capricor and its executives made false and misleading statements regarding the efficacy and safety data of deramiocel, particularly in relation to its Phase 2 HOPE-2 trial [4]. - Capricor received a Complete Response Letter (CRL) from the FDA on July 11, 2025, denying the Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [5]. Group 3: Stock Price Impact - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [6].